Medtronic

TAVI EVIDENCE UPDATE

# SURTAVI 5-year results

## Consistently good outcomes

CoreValve™ and Evolut™ TAVI platforms† maintained hemodynamic benefits and stable valve performance at five years in intermediate risk patients.

### Compared to SAVR at five years, CoreValve and Evolut TAVI platforms demonstrated:

1. No statistical difference in all-cause mortality
   30.0% (TAVI); 28.7% (SAVR) p = 0.55
2. Numerically lower disabling stroke
   4.1% (TAVI); 5.8% (SAVR) p = 0.12
3. Statistically better hemodynamics with stable low gradients

### Core-Lab Assessed Hemodynamics




All post-implant p-values are < 0.001

†Devices used: 84% CoreValve/16% Evolut R.

Reference: Van Mieghem NM. 5-Year Clinical and Echocardiographic Outcomes from the Randomized SURTAVI Trial. Presented at TCT 2021; November 5, 2021; Orlando, FL.

See the CoreValve™ Evolut™ R, the CoreValve™ Evolut™ PRO and the Evolut™ PRO+ device manuals for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, the commercial name of the Evolut™ PRO device is Medtronic CoreValve™ Evolut™ PRO System, and the commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System.

Medtronic

**Europe**
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00



**medtronic.eu**